Abiopharma

🔍 Brennan Aoife (Executive)

Company: Climb Bio, Inc. (CLYM)

Report Date: 2026-06-27

Detailed Transactions and Holdings:

• Acquired 68,750 shares of Common Stock (Direct)
  Date: 2026-06-27 | Code: M | equity_swap_involved: false | shares_owned_after: 118,633.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 30,902 shares of Common Stock at $13.17 per share (Direct)
  Date: 2026-06-29 | Code: S | equity_swap_involved: false | shares_owned_after: 87,731.00 | transaction_form_type: 4 | Footnotes: F3, F4
• Sold 68,750 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-27 | Code: M | equity_swap_involved: false | shares_owned_after: 137,500.00 | transaction_form_type: 4 | Footnotes: F5, F6, F6

Footnotes:

• F1: Each restricted stock unit ("RSU") converted into one share of the Issuer's Common Stock
• F2: Total includes an additional 1,751 shares acquired through the Company's Employee Stock Purchase Plan.
• F3: The sale reported on this Form 4 was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's RSUs.
• F4: The price reported is a weighted average price. These shares were sold in multiple transactions at prices within the range of $13.02 to $13.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
• F5: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
• F6: The RSUs were granted on June 27, 2024 (the "Grant Date") and are scheduled to vest over four years, with 25% of the shares vesting on each of the first four anniversaries of the Grant Date, subject to the Reporting Person's continued service.